| Project/Area Number |
22K15487
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 49070:Immunology-related
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
スルタン ソフィア・シェリル 東京医科歯科大学, 難治疾患研究所, 非常勤講師 (20838437)
|
|---|
| Project Period (FY) |
2022-04-01 – 2023-03-31
|
| Project Status |
Discontinued (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2023: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2022: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | CD72 / C1Q / SLE / CD72-C1q interaction |
|---|
| Outline of Research at the Start |
Systemic Lupus Erythematosus is a multi-faceted autoimmune disease. Our research is focused on understanding the development of this disease. We are trying to find a mechanistic explanation of the immune-modulatory role of the complement protein C1q which is strongly implicated with SLE development.
|
| Outline of Annual Research Achievements |
Systemic Lupus Erythematosus is an autoimmune disease in which B cells play an integral role through autoantibody secretion. Our lab has previously provided evidence of the involvement of CD72, an inhibitory B cell receptor in SLE development. In this project, we investigated the possibility that CD72 is a receptor for C1q ( a complement protein that binds to apoptotic cells ). Invitro studies showed an interaction between CD72 and C1q. For further investigation, functional analysis was done to study if a fusion protein composed of CD72 and C1q can inhibit B cell responses to apoptotic cells. To extend the scope of the study to an in vivo level, a targeting vector expressing a fusion protein composed of the globular domain of C1q fused to the CD72 receptor was created.
|
